537 related articles for article (PubMed ID: 9466277)
21. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties.
Kolb HJ
Vox Sang; 1998; 74 Suppl 2():321-9. PubMed ID: 9704463
[TBL] [Abstract][Full Text] [Related]
22. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).
Schiffer CA; Hehlmann R; Larson R
Leukemia; 2003 Apr; 17(4):691-9. PubMed ID: 12682626
[TBL] [Abstract][Full Text] [Related]
23. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
Martinelli G; Montefusco V; Testoni N; Amabile M; Saglio G; Ottaviani E; Terragna C; Bonifazi F; Rosti G; Bandini G; Tura S
Haematologica; 2000 Jun; 85(6):653-8. PubMed ID: 10870124
[TBL] [Abstract][Full Text] [Related]
25. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
Gaiger A; Lion T; Kalhs P; Mitterbauer G; Henn T; Haas O; Födinger M; Kier P; Forstinger C; Quehenberger P
Leukemia; 1993 Nov; 7(11):1766-72. PubMed ID: 8231244
[TBL] [Abstract][Full Text] [Related]
26. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
[TBL] [Abstract][Full Text] [Related]
27. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Porter DL; Roth MS; McGarigle C; Ferrara JL; Antin JH
N Engl J Med; 1994 Jan; 330(2):100-6. PubMed ID: 8259165
[TBL] [Abstract][Full Text] [Related]
28. Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis.
Leber B; Walker IR; Rodriguez A; McBride JA; Carter R; Brain MC
Bone Marrow Transplant; 1993 Oct; 12(4):405-7. PubMed ID: 8275041
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
30. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
[TBL] [Abstract][Full Text] [Related]
31. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
32. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.
Bogdanić V; Aurer I; Hitrec V; Boban D; Nemet D; Zupancić-Salek S; Labar B
Haematologica; 1995; 80(4):338-40. PubMed ID: 7590504
[TBL] [Abstract][Full Text] [Related]
33. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
[TBL] [Abstract][Full Text] [Related]
34. What does one do for the CML patient in relapse after allogeneic bone marrow transplantation?
Arcese W; Iori AP; Di Nucci G; Martinez-Rolon J; Pinto RM; Mandelli F
Leuk Lymphoma; 1993; 11 Suppl 1():213-9. PubMed ID: 8251899
[TBL] [Abstract][Full Text] [Related]
35. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
[TBL] [Abstract][Full Text] [Related]
36. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
37. Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
Maury S; Belhadj K; Chami I; Kuentz M; Cordonnier C; Bories D
Bone Marrow Transplant; 2001 Oct; 28(7):717-20. PubMed ID: 11704798
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia: management of relapse after allogeneic bone marrow transplantation.
Kumar L
Leuk Lymphoma; 1993 Jun; 10(3):165-71. PubMed ID: 8220114
[TBL] [Abstract][Full Text] [Related]
39. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
[TBL] [Abstract][Full Text] [Related]
40. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
